Mymetics Intangible Assets

What does Mymetics do? Mymetics Corp, listed under the ticker MYMX with ISIN US62856A3005, is a biotechnology company based in Epalinges, Switzerland. The company operates within the Health Care sector, specifically in the Biotechnology industry. Mymetics Corp has an employee count of 8 and went public on February 10, 1995. The company's website is https://www.mymetics.com/. Mymetics Corp focuses on the research and development of virosome-based vaccines for infectious diseases. Virosomes are lipid-based carriers that incorporate functional fusion viral proteins and natural membrane proteins, combined with rationally designed antigens. The company has multiple vaccine candidates in its pipeline, including those targeting HIV-1/AIDS, influenza, malaria, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). The HIV-1 vaccine candidate utilizes virosomes linked to conserved antigens derived from HIV-1 glycoprotein 41 (gp41) proteins of clade B. The RSV vaccine candidate is composed of reconstituted RSV membrane containing native viral proteins. Similarly, the HSV vaccine candidate consists of reconstituted membranes from HSV-1 or HSV-2, while the intranasal influenza vaccine includes reconstituted influenza virus membranes. Mymetics Corp's technology aims to develop prophylactic vaccines through these virosome-based approaches. The company's headquarters are located in Epalinges, Vaud, Switzerland. The firm's current focus is on advancing its pipeline of vaccine candidates for various infectious diseases through innovative virosome technology. Mymetics is one of the most popular companies on Eulerpool.